SOAT1 and dermatitis: Based on evidence that tofacitinib (a JAK1/2/3 inhibitor) rescues STAT hyperphosphorylation in vitro, the individual described by Gruber et al. was treated with tofacitinib, resulting in the resolution of her dermatitis and gastrointestinal symptoms (7).